Next Phase Newsletter

A healthcare and life sciences focused venture capital firm based in US and China has managed $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over 50 companies with 10 successful IPO and acquisitions. The firm seeks Series A to Series B opportunities in healthcare and life sciences. Typical check size ranges from $5-15 million USD. The firm prefers to lead, especially for US and China based deals but is open to co-investing. The firm primarily considers companies based in the US and China but is open to opportunities globally. 
 
The firm looks for new opportunities in therapeutics, medical devices, medical services, the diagnostics (IVD) space and healthcare IT. The firm is opportunistic in terms of subsectors and indications. For therapeutics, the firm would like to see some clinical data or safety data. 
 
The firm does not have specific requirements for the management team. Management teams with successful track records would be preferable. The firm will likely seek board seats on a case-by-case basis. 
 
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A Venture Capital firm based in Western Europe invests exclusively in the life science space and is currently investing out of their first fund. The firm looks to invest in early-stage life science companies crossing all sectors and is opportunistic in terms of subsector and indication. The firm focuses on Pre-Seed, Seed, Series A and Series B investments and investments are in the form of equity. The firm makes investments ranging from $50K to $3M per round. The firm will consider opportunities globally. 
 
In the life sciences, the firm is looking for new investment opportunities in the therapeutics, diagnostics, digital health, medical device and femtech sectors. The firm is open to pre-clinical therapeutic companies and all three classes of medical devices. The firm has a broad investment interest and is opportunistic in terms of sub-sectors and indications. 
 
The firm looks for all types of management teams, however a proven track record is a plus. The firm is open to both leading and co-investing. If the firm leads, they seek board seat representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a life science venture capital firm with strong China expertise and global capabilities. Founded in 2017, the firm discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in Boston, Shanghai, as well as Palo Alto. 
 
The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage. 
 
The firm has no specific requirement for the company & management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm founded in 2022 and headquartered in the US invests in cancer-focused data accessibility and scalability, infrastructure, education and access, and IT and service start-ups as they look to fundamentally change the way cancer care is designed and delivered at scale. Drugs, therapeutics, or medical devices are not of interest. The firm will invest in Seed stage companies that are currently selling in the market. The firm is open to global companies, typically allocating between $250k-1.5M USD. The firm can act as a lead investor and co-investor. 
 
In terms of life science, the firm invests in cancer-focused digital health companies, however, does not invest in drugs, therapeutics, medical devices, and technologies that require FDA approval. 
 
The firm does not have specific management team requirements and does not require to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital fund founded in 2020 and headquartered in California invests in life science and healthcare companies that focus on mental health and wellness. The firm prefers to invest in Seed rounds but is open to Pre-Seed as well, with typical check sizes ranging from $500k-700k USD. The firm is open to global companies. 

The firm is open to drugs, digital health, diagnostics, and device companies with indications in psychiatry, neurology, and neuropsychiatry. Some categories of interest include psychedelic medicine & new compounds, neurotech & human augmentation, precision psychiatry, digital therapeutics, holistic medicine, metabolic psychiatry, digital health, and AI. The firm can invest as early as pre-clinical and in-development stages. 

The firm can co-lead for Pre-Seed rounds and does not require to take a board seat. The firm prefers to have at least one co-founder be full-time. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A corporate venture arm of a leading global Contract Research, Development and Manufacturing Organization (CRDMO) founded in 2018 is open to investing in anywhere from seed to IPO financing rounds. Initial investment size can vary and follow-on investment is possible. The firm primarily seeks opportunities in the US, and is open to China and Europe as well. The venture arm does not lead rounds and prefers companies with a lead investor in place. Depending on the investment size and deal terms, the fund may consider an observer seat or board seat. The venture arm makes equity investments only and does not have an equity-for-service model. 
 
Separately from the corporate venture arm, the organizations runs a program that collaborates with over 25 partners, such as accelerators, seed/venture capital firms, incubators, and other similar programs to provide startups various tools and resources to accelerate biologics and vaccine development, including credits for the organization’s technology platforms. Startups must be an active participant or referred by a Program Partner to be eligible. 

The venture arm will consider a wide range of biotech assets, from antibody drug, protein therapeutics, vaccines, DNA and mRNA drugs. The fund is also open to orphan drugs. One type of asset that the fund does not consider cell and gene therapy. 

The venture arm does not lead rounds therefore would only invest when a lead investor is secured. The fund is open to working with new or first time founders but hopes to see that the team has a good supportive network. The fund is interested in working with founders who are open to advice and suggestions. 

The venture’s team is open to meeting with companies in their initial stage of fundraising and will track their progress. But they will only look deeper into the opportunities when a lead investor is in play and the company is close to signing a term sheet.  

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture fund founded in 2019 with headquarters in the Bay Area, an $100M AUM, and a current fund size of $50M USD, is dedicated towards medical device-centered technologies from Series A to C. The firm is open to earlier-stage opportunities if the project aligns with the firm’s interests. The typical initial check size is $1-5M, and the firm plans to make 4-5 investments in the next year. The firm invests globally with a focus in the United States. 

The firm invests in PMA and 510K medical devices, specifically those pertaining to surgical innovation, in development and clinical phases. The firm does not invest in heath information systems or wearables. Otherwise, the firm considers device-approached technologies in the therapeutics, diagnostics, and digital health space in development and clinical phases. While the firm is open to all indications, cardiology, neurology, and surgery are areas of interest. 

The firm does not have any requirements of the management team. The firm will both lead and co-lead depending on the area of expertise. Board seating will be required when leading investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.